Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...

UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement ...

Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in ...

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...

Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...

Wells Fargo keeps an Overweight rating and $68 price target on PTC Therapeutics (PTCT). Investors had been undervaluing the potential value of ...

William Blair analyst Sami Corwin has reiterated their bullish stance on PTCT stock, giving a Buy rating on November 27.Don't Miss our Black ...

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

A roundup of significant health updates globally includes Sanofi's major investment in China, New Zealand suspending poultry ...

RBC Capital has upgraded PTC Therapeutics (PTCT) to outperform from sector perform on the company’s deal with Novartis (NVS) for its Huntington’s disease program. Read more here.